Guerreiro HAM, Leyva RA, Villaescusa BR

Language: Spanish
References: 17
Page: 217-220
PDF size: 45.92 Kb.

Text Extraction

No abstract.

REFERENCES

1. Wedderburn LR, Mc Hugo NJ, Chinoy H, Cooper RG, Salway F, Ollier WE, et al. HLA class II haplotype and autoantibody association in children with juvenile dermatomiositis and juvenile dermatomiositis – scleroderma overlap. Rheumatology (Oxford). 2007 dec; 46(12):1786-91.

2. Scleroderma – like hands in a 16 years old boy diagnosis. Jama Dermatol 2013 jun; 5:2. doi: 10.1001/jamadermatol.2013.3370b.

3. Subcommittee for scleroderma criteria of the rheumatism association diagnostic and therapeutic criteria commitee. Preliminary criteria for the clasification of systemic sclerosis (scleroderma). Arthritis Rheum. 1980 May;23(5):581-90.

4. Nadaskevich O, Davis P, Fritzler MJ. A proposal of criteria for the classification of systemic sclerosis. Med Sci Monit. 2004 nov;10(11):CR 615-21.

5. Alimova E, Farhi D, Plantier F, Carlotti A, Gorin I, Mouthon L, et al. Morphoea (localized scleroderma): baseline body surface involvement and antinuclear antibody may have a prognostic value. Clin Exp Dermatol. 2009 oct;34(7):491-2.

6. Shake TL, Fonseca AE, Luciano AL, Azevedo PM. Autoantibodies in scleroderma and their association with the clinical profile on the disease a study of 66 patients from southern Brazil. An Bras Dermatol. 2012 nov-dec;86(6):1075-81.

7. Grassegger A, Pohla-Gubo G, Frauscher M, Hintner H. Autoantibodies in systemic sclerosis (scleroderma): Clues for clinical evolution, prognosis and pathogenesis. Wien Med Wochenschr. 2008;158(1-2):19-28.

8. Mierau R, Moinzadeh P, Riemekaslen G, Melchers I, Meurer M, Reichenberger F, et al. Frecuency of disease-associated and other nuclear autoantibodes in patient of the german network for systemic scleroderma: Correlation with characteristic clinical features. Artritis Res Ther. 2011 13(5):R172.

9. Muro Y, Sugiura K, Akiyama M. What test should become widely available to help scleroderma diagnosis and management. Arthritis Res Ther. 2013 jul 8;15(4):116.

10. Englert H, Champion D, Wu JC, Gialllusi J, Mc Grath M, Manolios N. Antitopoisomerasa antibody positivity predates nailfold capillaroscopy abnormalities in scleroderma. Postulated classification of prescleroderma. Intern Med J. 2011 feb;41(2):197-9.

11. Hamdouch K, Rodríguez C, Pérez–Venegas J, Rodríguez J, Astola A, Ortiz M, et al. Anti cenp autoantibodies in scleroderma patients with features of autoimmune liver disease. Clin Chim Acta. 2011 nov 20;412(23-24):2267-71.

12. Kim D, Peck A, Santer D, Patole P, Schwartz SM, Molitor JA, et al. Induction of interferon-alfha by scleroderma sera containing autoantibodies to topoisomerasa I: association of higher interferon – alpha activity with lung fibrosis. Artritis Rheum. 2008 jul; 58(7):2163-73.

13. Kuwama M, Okano Y, Kaburaki J, Inoko H. HLA class 2 associations with autoantibodies in scleroderma: A highly significant role for HLA-DP. Genes Immun. 2001 apr;2(2):76-81.

14. Al-mogaien SM. Role of sodium silicate in induction of sleroderma-related autoantiboies in brown Norway rats through oral and subcutaneous administration. Rheumatol Int. 2010;31(5):611-5.

15. Hanafusa T, Azukizawa H, Nishioka M, Tanemura A, Murota H, Yoshida H, et al. Lichen planus-type chronic graft-versus-host disease complicated by mucous membrana pemphigoid with positive anti-Bp 180/230 and scleroderma–related autoantibodies followed by reduce regulatory t cell frecuency. Eur J Dermatol. 2012 Jan-Feb;22(1):140-2.

16. Skare TL, Nisihara RM, Haider O, Azevedo PM, Utiyama SR. Liver autoantibodies in patients with scleroderma. Clin Rheumatol. 2011 Jan;30(1):129-32.

17. Kenna JG, Major GN, Williams RS. Methods for reducing non specific antibody binding in enzyme -linked Immunosorbent assays. J Immunol Methods. 1985 Dec 27;85(2):409-19.